• CT:VQ™, the world's first non-contrast, CT-based ventilation-perfusion imaging technology, receives CE Mark certification
• 4DMedical completes an $83 million private placement to fund the expansion and acceleration of CT:VQ™ into the EU
• The placement price represents a 6.1% discount to the last close and a 12.3% premium to the 5-day VWAP

4DMedical Limited, a global leader in respiratory imaging technology, has announced that its CT:VQ™ solution, the world's first and only non-contrast, CT-based ventilation-perfusion imaging technology, has received CE Mark certification for commercial use in the European Union (EU). Coinciding with this regulatory milestone, the company has completed an $83 million single-tranche private placement at an issue price of $5.90 per share. The placement price represents a 6.1% discount to the last closing price and a 12.3% premium to the 5-day VWAP. The proceeds from the placement will be used to fund the commercial launch of CT:VQ™ across Europe and international markets, support clinical integration for new customers, and strengthen the balance sheet to pursue strategic growth opportunities, including potential acquisitions. The EU represents a significant commercial opportunity for CT:VQ™, with a population exceeding 450 million and a highly developed hospital-based imaging infrastructure. CE Mark certification enables 4DMedical to immediately engage with key healthcare providers across the EU, supporting clinical adoption, commercial rollout, and collaboration with leading respiratory centres. Beyond the direct commercial opportunity, Europe plays a critical role in shaping global clinical practice in respiratory imaging, and regulatory clearance enhances 4DMedical's ability to engage with clinicians, support locally led research, and contribute to the global evidence base for CT:VQ™.

The company is already developing exciting plans to deploy the capital raised from the placement in Europe, and plans to share these plans with investors before the end of FY26.